Literature DB >> 7499276

Concordant loss of imprinting of the human insulin-like growth factor II gene promoters in cancer.

S Zhan1, D Shapiro, S Zhan1, L Zhang, S Hirschfeld, J Elassal, L J Helman.   

Abstract

The human insulin-like growth factor II (IGFII) gene has been shown to be imprinted for the promoters P2, P3, and P4 but not for the promoter P1 in liver and chondrocytes. Loss of imprinting of the IGFII gene has been found in a variety of human tumors including rhabdomyosarcoma and lung cancer. In this report, we determined whether loss of imprinting in tumors displays a promoter-specific pattern. We examined allelic expression of all four IGFII promoters in rhabdomyosarcoma, lung cancer, and normal skeletal muscle. We demonstrate that the imprinting of all IGFII promoters is relaxed in rhabdomyosarcoma and lung cancer. These data suggest that loss of imprinting of IGFII gene promoters may be regulated coordinately by a common mechanism in these tumors. Unexpectedly, we also found that P1, in addition to P2, P3, and P4 is monoallelically expressed in three informative adult skeletal muscle tissues. This indicates that imprinting of the IGFII promoter P1 occurs in a tissue-specific manner.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7499276     DOI: 10.1074/jbc.270.47.27983

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Transcriptional regulation and biological significance of the insulin like growth factor II gene.

Authors:  W Engström; A Shokrai; K Otte; M Granérus; A Gessbo; P Bierke; A Madej; M Sjölund; A Ward
Journal:  Cell Prolif       Date:  1998 Oct-Dec       Impact factor: 6.831

2.  Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.

Authors:  Dong Hoon Shin; Hye-Young Min; Adel K El-Naggar; Scott M Lippman; Bonnie Glisson; Ho-Young Lee
Journal:  Mol Cancer Ther       Date:  2011-10-06       Impact factor: 6.261

3.  Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis.

Authors:  J P Issa; P M Vertino; C D Boehm; I F Newsham; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications.

Authors:  Djeda Belharazem; Julia Magdeburg; Ann-Kristin Berton; Li Beissbarth; Christian Sauer; Carsten Sticht; Alexander Marx; Ralf Hofheinz; Stefan Post; Peter Kienle; Philipp Ströbel
Journal:  J Gastroenterol       Date:  2016-03-17       Impact factor: 7.527

5.  H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression.

Authors:  E Adriaenssens; L Dumont; S Lottin; D Bolle; A Leprêtre; A Delobelle; F Bouali; T Dugimont; J Coll; J J Curgy
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

Review 6.  A mouse model for medulloblastoma and basal cell nevus syndrome.

Authors:  R B Corcoran; M P Scott
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

7.  Insulin-like growth factor 2 is required for progression to advanced medulloblastoma in patched1 heterozygous mice.

Authors:  Ryan B Corcoran; Tal Bachar Raveh; Monique T Barakat; Eunice Y Lee; Matthew P Scott
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

8.  The role of insulin-like growth factor system in soft tissue sarcomas: from physiopathology to targeted therapeutic approaches.

Authors:  W Zumkeller
Journal:  Sarcoma       Date:  1998
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.